NCT05381181View on ClinicalTrials.gov

Safety and Efficacy Evaluation of Next-generation CD19-UCART

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

May 30, 2024

Study Completion Date

May 3, 2026

Conditions
Acute Lymphoblastic LeukemiaNon Hodgkin Lymphoma
Interventions
BIOLOGICAL

CD19-UCART

A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.

Sponsors
All Listed Sponsors
collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

lead

Bioray Laboratories

INDUSTRY

NCT05381181 - Safety and Efficacy Evaluation of Next-generation CD19-UCART | Biotech Hunter | Biotech Hunter